Defined as immune mediated chronic liver diseases of unknown etiology. Their incidence has recently increased due to greater awareness of the diseases and development of new diagnostics techniques. Serology is mainly based upon screening for marker autoantibodies that are crucial for the correct diagnosis and classification of the diseases.
Primary Biliary Cirrhosis (PBC)
The following autoimmune antibodies are useful for the detection of PBC; anti-mitochondrial antibodies (AMA), M2, gp210, sp100.
Autoimmune Hepatitis (AIH)
The following autoimmune antibodies are useful for the detection of AIH; Liver Kidney Microsome (LKM-1), LC1, SLA, SMA, f-actin.
Initial screening is usually performed by IFA using liver and kidney tissue which primarily picks up AMA patterns for PBC and LKM patterns for AIH.
Patients are then characterised typically using the BlueDiver Dot assays such as LI10DIV-24 which detects; M2/nPDC, M2/OGDC-E2, M2/BCOADC-E2, M2/PDC-E2, gp210, sp100, LKM1, LC1, SLA and f-actin. This aids with differentiating between AIH type 1 and type 2. LC1 autoantibodies tend to be overlooked when looking at IFA patterns due to the bright LKM patterns which makes BlueDiver Dot assays ideal for detecting their presence.
|Code||Description||MSDS||Instructions for use|
|FA3403||AAS Mouse Kidney/Stomach/Liver Tissue Test System|
|LI10DIV-24||BlueDiver Dot Liver 10 Parameters|